Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?

Kristian Doyle, Marion S. Buckwalter

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Post-stroke cognitive decline and dementia pose a significant public health problem, with 30% of stroke survivors suffering from dementia. The reason for this high prevalence is not well understood. Pathogenic B cell responses to the damaged CNS are one possible contributing factor. B-lymphocytes and antibodies are present in and around the stroke core of some human subjects who die with stroke and dementia, and mice that develop delayed cognitive dysfunction after stroke have clusters of B-lymphocytes in the stroke lesion, and antibody infiltration in the stroked hemisphere. The ablation of B-lymphocytes prevents post-stroke cognitive impairment in mice. Multiple drugs that target B cells are FDA approved, and so if pathogenic B cell responses are occurring in a subset of stroke patients, this is potentially treatable. However, it has also been demonstrated that regulatory B cells can be beneficial in mouse models of stroke. Consequently, it is important to understand the relative contribution of B-lymphocytes to recovery versus pathogenicity, and if this balance is heterogeneous in different individuals. Therefore, the purpose of this review is to summarize the current state of knowledge with regard to the role of B-lymphocytes in the etiology of post-stroke dementia.

Original languageEnglish (US)
JournalBrain, Behavior, and Immunity
DOIs
StateAccepted/In press - May 24 2016

Fingerprint

Autoimmunity
Dementia
B-Lymphocytes
Stroke
Regulatory B-Lymphocytes
Antibodies
Virulence
Survivors
Public Health

Keywords

  • Alzheimer's Disease
  • Autoantibody
  • Autoimmune
  • Dementia
  • Lymphocyte
  • Stroke
  • Vascular dementia

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia? / Doyle, Kristian; Buckwalter, Marion S.

In: Brain, Behavior, and Immunity, 24.05.2016.

Research output: Contribution to journalArticle

@article{90330bd6a01644febf21aa41a1f561fc,
title = "Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?",
abstract = "Post-stroke cognitive decline and dementia pose a significant public health problem, with 30{\%} of stroke survivors suffering from dementia. The reason for this high prevalence is not well understood. Pathogenic B cell responses to the damaged CNS are one possible contributing factor. B-lymphocytes and antibodies are present in and around the stroke core of some human subjects who die with stroke and dementia, and mice that develop delayed cognitive dysfunction after stroke have clusters of B-lymphocytes in the stroke lesion, and antibody infiltration in the stroked hemisphere. The ablation of B-lymphocytes prevents post-stroke cognitive impairment in mice. Multiple drugs that target B cells are FDA approved, and so if pathogenic B cell responses are occurring in a subset of stroke patients, this is potentially treatable. However, it has also been demonstrated that regulatory B cells can be beneficial in mouse models of stroke. Consequently, it is important to understand the relative contribution of B-lymphocytes to recovery versus pathogenicity, and if this balance is heterogeneous in different individuals. Therefore, the purpose of this review is to summarize the current state of knowledge with regard to the role of B-lymphocytes in the etiology of post-stroke dementia.",
keywords = "Alzheimer's Disease, Autoantibody, Autoimmune, Dementia, Lymphocyte, Stroke, Vascular dementia",
author = "Kristian Doyle and Buckwalter, {Marion S.}",
year = "2016",
month = "5",
day = "24",
doi = "10.1016/j.bbi.2016.08.009",
language = "English (US)",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?

AU - Doyle, Kristian

AU - Buckwalter, Marion S.

PY - 2016/5/24

Y1 - 2016/5/24

N2 - Post-stroke cognitive decline and dementia pose a significant public health problem, with 30% of stroke survivors suffering from dementia. The reason for this high prevalence is not well understood. Pathogenic B cell responses to the damaged CNS are one possible contributing factor. B-lymphocytes and antibodies are present in and around the stroke core of some human subjects who die with stroke and dementia, and mice that develop delayed cognitive dysfunction after stroke have clusters of B-lymphocytes in the stroke lesion, and antibody infiltration in the stroked hemisphere. The ablation of B-lymphocytes prevents post-stroke cognitive impairment in mice. Multiple drugs that target B cells are FDA approved, and so if pathogenic B cell responses are occurring in a subset of stroke patients, this is potentially treatable. However, it has also been demonstrated that regulatory B cells can be beneficial in mouse models of stroke. Consequently, it is important to understand the relative contribution of B-lymphocytes to recovery versus pathogenicity, and if this balance is heterogeneous in different individuals. Therefore, the purpose of this review is to summarize the current state of knowledge with regard to the role of B-lymphocytes in the etiology of post-stroke dementia.

AB - Post-stroke cognitive decline and dementia pose a significant public health problem, with 30% of stroke survivors suffering from dementia. The reason for this high prevalence is not well understood. Pathogenic B cell responses to the damaged CNS are one possible contributing factor. B-lymphocytes and antibodies are present in and around the stroke core of some human subjects who die with stroke and dementia, and mice that develop delayed cognitive dysfunction after stroke have clusters of B-lymphocytes in the stroke lesion, and antibody infiltration in the stroked hemisphere. The ablation of B-lymphocytes prevents post-stroke cognitive impairment in mice. Multiple drugs that target B cells are FDA approved, and so if pathogenic B cell responses are occurring in a subset of stroke patients, this is potentially treatable. However, it has also been demonstrated that regulatory B cells can be beneficial in mouse models of stroke. Consequently, it is important to understand the relative contribution of B-lymphocytes to recovery versus pathogenicity, and if this balance is heterogeneous in different individuals. Therefore, the purpose of this review is to summarize the current state of knowledge with regard to the role of B-lymphocytes in the etiology of post-stroke dementia.

KW - Alzheimer's Disease

KW - Autoantibody

KW - Autoimmune

KW - Dementia

KW - Lymphocyte

KW - Stroke

KW - Vascular dementia

UR - http://www.scopus.com/inward/record.url?scp=85004190436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004190436&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2016.08.009

DO - 10.1016/j.bbi.2016.08.009

M3 - Article

C2 - 27531189

AN - SCOPUS:85004190436

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -